Latest Breaking News On - Committee for medicinal products human - Page 7 : comparemela.com

AstraZeneca: Voydeya approved in the EU as a treatment for HPN

AstraZeneca announces that Voydeya has been approved in the European Union as an adjunct to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria .

Form 20-F Achilles Therapeutics For: Dec 31

FDA approves Basilea's intravenous antibiotic Zevtera for three indications

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults -March 28, 2024 at 06:46 am EDT

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in.

Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC